Arena rallies on FDA optimism; Vivus shares halted

Investors bid shares of diet-drug developer Arena Pharmaceuticals higher, ahead of a Food and Drug Administration panel meeting on a weight-loss product candidate made by rival Vivus. GlaxoSmithKline gains in the wake of FDA panel's recommendation on Avandia drug.